4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness

Core Insights - 4D Molecular Therapeutics announced senior leadership changes to enhance focus on late-stage clinical trials and commercial readiness for its lead product candidate, 4D-150 [1][2][3] Leadership Changes - Dr. Julie Clark has been appointed as the new Chief Medical Officer, bringing over 20 years of experience in retina and global clinical development, including leadership roles in multiple BLA submissions and Phase 3 trials [3][5] - Liansheng Zhu, Ph.D., has joined as Senior Vice President of Biometrics and Data Quality, contributing nearly two decades of experience in late-stage clinical development and regulatory submissions [4][5] - Robert Kim, M.D., has stepped down from his role as Chief Medical Officer to pursue other opportunities [5] Clinical Development Focus - The 4FRONT-1 Phase 3 clinical trial for 4D-150 is on track to complete enrollment by Q1 2026, with current enrollment exceeding expectations [4][5] - 4D-150 is positioned as a backbone therapy for retinal vascular diseases, specifically targeting wet age-related macular degeneration and diabetic macular edema [8] Strategic Enhancements - The addition of senior retina leadership advisors aims to support the transition from late-stage development to commercial readiness [4] - The company emphasizes the importance of shared experience and complementary strengths among its leadership team to advance the 4D-150 program [3][5]